2021
DOI: 10.1101/2021.12.14.21267714
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Hepatitis C subtyping assay failure in UK patients born in Sub-Saharan Africa: implications for global treatment and elimination

Abstract: The newly developed direct-acting antivirals (DAAs) have revolutionised the treatment of chronic hepatitis C virus (HCV), where cohort studies have shown that cure rates as high as 98% can be achieved. Whilst genome sequencing has demonstrated that some subtypes of HCV naturally harbour drug resistance associated substitutions (RAS), these have not been considered important as previous molecular epidemiological studies have suggested that such difficult-to-treat subtypes are rare. Therefore, to optimise and st… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 44 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?